SALT LAKE CITY, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN) (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced select unaudited preliminary results ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results